Abstract
Nanobodies (Nb) have a promising future as a part of next generation chemodrug delivery systems. Nb, or VHH, are small (15 kDa) monomeric antibody fragments consisting of the antigen binding region of heavy chain antibodies. Heavy chain antibodies are naturally produced by camelids, however the structure of their VHH regions can be readily reproduced in industrial expression systems, such as bacteria or yeast. Due to their small size, high solubility, remarkable stability, manipulatable characteristics, excellent in vivo tissue penetration, conjugation advantages, and ease of production, Nb have many advantages when compared against their antibody precursors. In this review, we discuss the generation and selection of Nbs via phage display libraries for easy screening, and the conjugation techniques involved in creating target-specific nanocarriers. Furthermore, we provide a comprehensive overview of recent developments and perspectives in the field of Nb drug conjugates (NDCs) and Nb-based drug vehicles (NDv) with respect to antitumor therapeutics.
| Original language | English |
|---|---|
| Pages (from-to) | 389-412 |
| Number of pages | 24 |
| Journal | Journal of Controlled Release |
| Volume | 334 |
| DOIs | |
| State | Published - Jun 10 2021 |
Keywords
- Antibody drug conjugates (ADCs)
- Camelid nanobody (VHH)
- Cancer-biomarker
- Conjugation strategy
- Drug delivery
- Nanobody drug conjugates (NDCs)
- Phage-display technique
Fingerprint
Dive into the research topics of 'Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver